UGX202 Injection in Patients With Advanced Retinitis Pigmentosa

Inclusion Criteria: * Provide written informed consent form (ICF). * Age ≥18 years at ICF signing. * Diagnosed as non-syndromic RP； * BCVA \> logMAR 1.9 (assessed by FrACT) in the study eye. * Confirmation of preserved memory of visual experience * Spherical equivalent between -9D and +6D. Exclusion Criteria: * Prior gene therapy in either eye. * Received any interventional investigational drug within 90 days prior to screening. * Any Study eye disease or systemic disease judged by the investigator to affect visual function assessment. * Hypersensitivity to corticosteroids, intolerance to corticosteroid regimen, active concurrent infection contraindicating treatment. * History or tendency of psychiatric disorders impacting safety and/or efficacy assessment. * Any other factor deemed unsuitable by the investigator.